דלג לתוכן הראשי
Lifestyle

Aubrey de Grey: The Architect of Longevity Explains the 1000-Year Vision

Dr. Aubrey de Grey, the man who a decade ago was considered a mad prophet and two years ago was seen as the visionary of the longevity industry, has opened a new research front at the LEV Foundation. In a comprehensive interview, he returns to the 7 types of cellular damage he identified as the root of aging, and explains why he is more convinced than ever that we are approaching "longevity escape velocity" - the point where each year of research adds more than a year to our lives.

📅02/05/2026 ⏱️5 דקות קריאה ✍️Reverse Aging 👁️45 צפיות

In the world of science, there are many researchers who talk big. Only a few manage to turn their vision into an entire industry. Dr. Aubrey de Grey is one of them. A British biologist with a climbing beard who has been discussing longevity for three decades, he was considered a marginal figure in science for years - until science itself turned in his direction. In an exclusive interview published this week, he returned to his vision: A person who is today 50 years old or younger could live for centuries, if research progresses at the current pace.

Who is Aubrey de Grey?

De Grey grew up in British academia, earned a bachelor's degree in computer science from Cambridge, and turned to biology as a second field. In 2002, he published the theory that became a cornerstone of the field: SENS - Strategies for Engineered Negligible Senescence. Instead of seeing aging as a mysterious irreversible process, he proposed an engineering framework: Aging is the accumulation of 7 defined types of cellular damage. Fix the damage - stop aging.

The Seven Types of Cellular Damage

According to de Grey, everything we call "aging" stems from a combination of seven cellular processes. Each requires its own solution:

  • Cell Loss and Atrophy: Cells that die and are not replaced. Solution: Stem cells and regenerative medicine.
  • Zombie Cells - Senescence: Cells that don't die when they should. Solution: Senolytics like dasatinib + quercetin.
  • Intracellular Junk Accumulation: Damaged proteins that cleaning enzymes cannot break down. Solution: Bacterial enzymes capable of digesting them.
  • Extracellular Junk Accumulation: Like beta-amyloid in Alzheimer's. Solution: Immunotherapy.
  • Crosslinks: Connective tissue proteins that bind to each other, making skin and arteries stiff. Solution: AGE-breaking enzymes.
  • Nuclear Mutations: Cancer. Solution: WILT - a method to shorten telomeres in all cells except stem cells.
  • Mitochondrial Mutations: Damage to mitochondrial DNA. Solution: Transferring these genes to the cell nucleus.

From SENS to LEV Foundation

In 2021, de Grey left the SENS Research Foundation after 18 years as founder and chief science officer, following an internal investigation. A year later, he founded the LEV Foundation - Longevity Escape Velocity Foundation. The name reflects his core belief: there is a point after which the pace of medical progress exceeds the pace of aging itself, and each year of research adds more than one year of life to us. According to de Grey, we may be about 15 years away from it.

The Decisive Experiment: 21-Month-Old Mice

At the center of LEV's new work is an ambitious experiment: taking mice in mid-life (21 months, equivalent to 60-year-old humans) and treating them simultaneously with a combination of several interventions. The expectation is that the combination will extend the mice's lifespan by 50% or more. To date, single experiments have succeeded in extending mouse lifespan by 25-30% with one intervention. De Grey believes the combination will have a synergistic effect, not just additive.

The 1000-Year Vision

De Grey's most famous statement, from 2004: "The first person to reach age 1000 has already been born". In the current interview, he sticks to the vision but with new caution: "I can't give a date. I can say that if we continue like this, and there is enough funding, the probability that this will happen within 30-40 years is significant."

Critics and Controversy

De Grey is not without critics. Traditional gerontologists argue that the 7-damage theory is too simplistic, and that aging involves systems more fragile than the sum of their components. Others point out that any success in the lab is far from humans. De Grey himself agrees there is a gap, but insists it is engineering, not biological: "We know what the problems are. Now we need to move this to the clinic."

What Does This Mean for Us?

Even if the 1000-year vision is distant, de Grey's approach has directly influenced drugs already reaching the clinic: senolytics, mTOR inhibitors (like rapamycin), NAD+ treatments, and combinations of senolytics + senomorphics. If you've ever wondered why all the newspaper headlines about anti-aging drugs have emerged in the last decade - a significant part of the explanation goes back to one man with a long beard who told everyone, 25 years ago, that all of this is possible.

References:
LEV Foundation
SENS Research Foundation

מקורות וציטוטים

💬 תגובות (0)

תגובות אנונימיות מוצגות לאחר אישור.

היו הראשונים להגיב על המאמר.